Publicado 27/02/2017 14:49
- Comunicado -

ALK's ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunother

CONTACT: For further information please contact:Media: Jeppe Ilkjær, tel. +45-7877-4532, mobile +45-3050-2014, InvestorRelations: Per Plotnikof, tel. +45-4574-7527, mobile +45 2261-2525

Contenido patrocinado